Crossmark

Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo

Crossref DOI link: https://doi.org/10.1186/s13046-018-0690-x

Published Online: 2018-02-20

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Guo, Xiaoran

To, Kenneth K. W.

Chen, Zhen

Wang, Xiaokun

Zhang, Jianye

Luo, Min

Wang, Fang

Yan, Shirong

Fu, Liwu
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (No.81673463)

Guangzhou Technology Program Foundation (No.201504010038, NO.201604020079)

The Science and Technology project of Guangdong Province (No.2014B050504004)

The science and Technology of Guangdong Province (No.2016A030312014)
More Information

Article History

Received: 5 November 2017

Accepted: 24 January 2018

First Online: 20 February 2018

Ethics approval and consent to participate

: We confirmed that all the protocols concerning animal experiments were approved by the ethics committee of Sun Yat-sen university Cancer center (NO. L10201201760I).

: We have obtained consents to publish this paper from all the participants of this study.

: The authors declare no conflict of interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.